LATEST 2026/2027 NR 507 ADVANCED PATHOPHYSIOLOGY
PRACTICE EXAM (100 QUESTIONS) INSTANT PDF
CORE DOMAINS
• Cellular Adaptation, Injury, and Neoplasia
• Genetics and Genomics in Disease
• Inflammation, Immunity, and Hypersensitivity
• Fluid, Electrolyte, and Acid-Base Disturbances
• Cardiovascular and Hematologic Pathophysiology
• Respiratory and Renal Pathophysiology
• Gastrointestinal and Hepatic Pathophysiology
• Endocrine and Metabolic Disorders
• Neurological and Musculoskeletal Pathophysiology
• Multisystem Disorders and Shock States
INTRODUCTION
This comprehensive practice examination is designed to evaluate the
advanced pathophysiological knowledge required for graduate-level
nursing education at Chamberlain University. The assessment covers
foundational and complex biological mechanisms underlying disease
processes across all major organ systems. The multiple-choice format
integrates clinical scenarios requiring synthesis of cellular biology,
immunology, genetics, and systemic physiology to explain disease
manifestations and anticipate complications. Candidates are expected to
demonstrate mastery of disease etiology, progression, and systemic
effects necessary for advanced clinical reasoning and evidence-based
practice. This examination serves as a rigorous evaluation of readiness
for advanced nursing practice.
,SECTION ONE: QUESTIONS 1–100
1. A patient with a history of atherosclerosis presents with chest
pain. Which cellular adaptation is most likely occurring in the
coronary arteries?
A. Hyperplasia
B. Hypertrophy
C. Metaplasia
D. Dysplasia
B. Hypertrophy
RATIONALE: Atherosclerosis leads to increased workload on the
heart due to narrowed coronary arteries. This results in myocardial
hypertrophy, which is an increase in cell size in response to increased
demand. Hyperplasia is an increase in cell number; metaplasia is a
change in cell type; dysplasia is abnormal cellular growth.
2. A patient with chronic gastroesophageal reflux disease (GERD)
develops Barrett's esophagus. This condition is an example of:
A. Hyperplasia
B. Dysplasia
C. Metaplasia
D. Anaplasia
C. Metaplasia
RATIONALE: Barrett's esophagus is a classic example of
metaplasia, where the normal squamous epithelium of the esophagus is
replaced by columnar epithelium resembling that of the stomach or
intestine. This occurs as an adaptive response to chronic acid exposure.
,3. A patient with a malignant tumor is at risk for metastasis. Which
step is essential for metastasis to occur?
A. Loss of cell adhesion and invasion
B. Increased apoptosis
C. Decreased angiogenesis
D. Decreased cellular motility
A. Loss of cell adhesion and invasion
RATIONALE: Metastasis requires loss of cell adhesion (enabling
detachment from the primary tumor), invasion into surrounding tissues,
and movement through blood or lymphatic vessels. Increased
angiogenesis is needed for metastasis; decreased apoptosis and increased
motility are also hallmarks.
4. A patient with a genetic predisposition to breast cancer has a
mutation in which tumor suppressor gene?
A. BRCA1
B. HER2
C. TP53
D. BRCA2
A. BRCA1
RATIONALE: BRCA1 and BRCA2 are tumor suppressor genes.
Mutations in BRCA1 and BRCA2 increase the risk of breast and ovarian
cancers. BRCA1 is most commonly associated with hereditary breast
and ovarian cancer syndrome. HER2 is an oncogene; TP53 is also a
tumor suppressor.
5. The normal function of the p53 gene (TP53) is to:
, A. Promote cell division
B. Suppress tumor formation by regulating cell cycle and apoptosis
C. Activate oncogenes
D. Increase angiogenesis
B. Suppress tumor formation by regulating cell cycle and apoptosis
RATIONALE: The p53 gene is a tumor suppressor that regulates the
cell cycle and promotes apoptosis (programmed cell death) in damaged
cells. It is often called the "guardian of the genome." Loss of p53
function contributes to cancer.
6. A patient with cancer is receiving chemotherapy that targets
rapidly dividing cells. Which phase of the cell cycle is the primary
target of most chemotherapeutic agents?
A. G1 phase
B. S phase
C. G2 phase
D. M phase
B. S phase
RATIONALE: Many chemotherapeutic agents (e.g., antimetabolites
like methotrexate) target the S phase (DNA synthesis phase) of the cell
cycle. Other agents target specific phases; cell cycle-specific drugs are
most effective against rapidly dividing tumor cells.
7. A patient with chronic inflammation is at increased risk for
cancer due to:
A. Decreased immune surveillance
B. Release of growth factors and reactive oxygen species (ROS)
PRACTICE EXAM (100 QUESTIONS) INSTANT PDF
CORE DOMAINS
• Cellular Adaptation, Injury, and Neoplasia
• Genetics and Genomics in Disease
• Inflammation, Immunity, and Hypersensitivity
• Fluid, Electrolyte, and Acid-Base Disturbances
• Cardiovascular and Hematologic Pathophysiology
• Respiratory and Renal Pathophysiology
• Gastrointestinal and Hepatic Pathophysiology
• Endocrine and Metabolic Disorders
• Neurological and Musculoskeletal Pathophysiology
• Multisystem Disorders and Shock States
INTRODUCTION
This comprehensive practice examination is designed to evaluate the
advanced pathophysiological knowledge required for graduate-level
nursing education at Chamberlain University. The assessment covers
foundational and complex biological mechanisms underlying disease
processes across all major organ systems. The multiple-choice format
integrates clinical scenarios requiring synthesis of cellular biology,
immunology, genetics, and systemic physiology to explain disease
manifestations and anticipate complications. Candidates are expected to
demonstrate mastery of disease etiology, progression, and systemic
effects necessary for advanced clinical reasoning and evidence-based
practice. This examination serves as a rigorous evaluation of readiness
for advanced nursing practice.
,SECTION ONE: QUESTIONS 1–100
1. A patient with a history of atherosclerosis presents with chest
pain. Which cellular adaptation is most likely occurring in the
coronary arteries?
A. Hyperplasia
B. Hypertrophy
C. Metaplasia
D. Dysplasia
B. Hypertrophy
RATIONALE: Atherosclerosis leads to increased workload on the
heart due to narrowed coronary arteries. This results in myocardial
hypertrophy, which is an increase in cell size in response to increased
demand. Hyperplasia is an increase in cell number; metaplasia is a
change in cell type; dysplasia is abnormal cellular growth.
2. A patient with chronic gastroesophageal reflux disease (GERD)
develops Barrett's esophagus. This condition is an example of:
A. Hyperplasia
B. Dysplasia
C. Metaplasia
D. Anaplasia
C. Metaplasia
RATIONALE: Barrett's esophagus is a classic example of
metaplasia, where the normal squamous epithelium of the esophagus is
replaced by columnar epithelium resembling that of the stomach or
intestine. This occurs as an adaptive response to chronic acid exposure.
,3. A patient with a malignant tumor is at risk for metastasis. Which
step is essential for metastasis to occur?
A. Loss of cell adhesion and invasion
B. Increased apoptosis
C. Decreased angiogenesis
D. Decreased cellular motility
A. Loss of cell adhesion and invasion
RATIONALE: Metastasis requires loss of cell adhesion (enabling
detachment from the primary tumor), invasion into surrounding tissues,
and movement through blood or lymphatic vessels. Increased
angiogenesis is needed for metastasis; decreased apoptosis and increased
motility are also hallmarks.
4. A patient with a genetic predisposition to breast cancer has a
mutation in which tumor suppressor gene?
A. BRCA1
B. HER2
C. TP53
D. BRCA2
A. BRCA1
RATIONALE: BRCA1 and BRCA2 are tumor suppressor genes.
Mutations in BRCA1 and BRCA2 increase the risk of breast and ovarian
cancers. BRCA1 is most commonly associated with hereditary breast
and ovarian cancer syndrome. HER2 is an oncogene; TP53 is also a
tumor suppressor.
5. The normal function of the p53 gene (TP53) is to:
, A. Promote cell division
B. Suppress tumor formation by regulating cell cycle and apoptosis
C. Activate oncogenes
D. Increase angiogenesis
B. Suppress tumor formation by regulating cell cycle and apoptosis
RATIONALE: The p53 gene is a tumor suppressor that regulates the
cell cycle and promotes apoptosis (programmed cell death) in damaged
cells. It is often called the "guardian of the genome." Loss of p53
function contributes to cancer.
6. A patient with cancer is receiving chemotherapy that targets
rapidly dividing cells. Which phase of the cell cycle is the primary
target of most chemotherapeutic agents?
A. G1 phase
B. S phase
C. G2 phase
D. M phase
B. S phase
RATIONALE: Many chemotherapeutic agents (e.g., antimetabolites
like methotrexate) target the S phase (DNA synthesis phase) of the cell
cycle. Other agents target specific phases; cell cycle-specific drugs are
most effective against rapidly dividing tumor cells.
7. A patient with chronic inflammation is at increased risk for
cancer due to:
A. Decreased immune surveillance
B. Release of growth factors and reactive oxygen species (ROS)
